Tumor-Targeted Genetic Drug Achieves Remission in Stage IV Prostate Cancer Patient

This is from a company press release that was picked up by Reuters and other news agencies.

”SAN MARINO, Calif., Oct. 12

“Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world’s first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again accomplished what standard cancer treatments and even much-touted biologics have failed to do: that is, to bring forth the benefits of remission in otherwise intractable metastatic cancers.

“Three recent cases of Stage IV metastatic cancer, namely (i) osteosarcoma, (ii) prostate cancer, and (iii) pancreas cancer, demonstrated that Rexin-G treatments alone led to clinical remission of disease in each of these poor prognosis patients. Even more
remarkable, perhaps, are the profiles of the latter two patients, which
signal the advent of Rexin-G as the vanguard of a new class of exceedingly precise, selective, and effective anti-cancer agents, and which typify newfound societal acceptance and acknowledgement of the real-world promise and potential of this uniquely-targeted genetic medicine.

“Remarkably, a Catholic priest, who was previously bedridden and in withering pain, suffering from end-stage prostate cancer that had spread to his bones, received successive courses of Rexin-G, during which time the bone pain was
relieved, the PSA tumor markers fell, the bone tumors stopped growing, and
even the previously inoperable primary tumor disappeared on follow-up CT scans. As the priest’s bones began to heal and strengthen, he arose from his bed and is currently saying daily Mass and delivering lectures in the seminary. What is even more remarkable is that this revered man of the cloth was over ninety years old at the time of his treatment and remission. . . “